While artificial intelligence, machine learning, and analytics dominate the headlines, biopharmaceutical companies’ ability to benefit from these advanced technologies is typically limited by a lack of solid data governance.
Despite these limitations, many businesses are hesitant to take the needed steps to develop a solid data governance foundation. This white paper discusses common data governance myths and lays out the key components of a successful data governance program that can be implemented by any biopharma company.
